10 Fastest Growing NASDAQ Stocks to Buy

4. ImmunityBio, Inc. (NASDAQ:IBRX)

On February 23, 2026, H.C. Wainwright raised its price target on ImmunityBio, Inc. (NASDAQ:IBRX) to $15 from $10 and maintained a Buy rating on the shares. The analyst said the recent European Union approval expands Anktiva’s footprint to 33 countries, “removing a major regulatory overhang” and opening a “meaningful incremental commercial opportunity.”

That same day, ImmunityBio reported Q4 EPS of (6c), compared to the (10c) consensus estimate. Q4 revenue was $38.29M versus consensus of $37.78M. President and CEO Richard Adcock said the company’s 2025 financial results reflect the growing clinical adoption of Anktiva “as a foundational backbone of immunotherapy for bladder cancer.” He noted that the partnership with Accord Healthcare deploys over 100 commercial professionals across 30 European countries and that collaboration with BioPharma & Cigalah supports commercial execution in Saudi Arabia and the broader MENA region. Adcock stated that with subsidiaries in Dublin and the Kingdom of Saudi Arabia, the company has infrastructure to support growth across all 33 countries where Anktiva is authorized. He added that the company remains focused on completing enrollment in its BCG-naive randomized trial with a BLA filing targeted by Q4 2026, expanding the Anktiva label into lung cancer and lymphopenia, and converting its “700% revenue growth trajectory” into durable value for shareholders.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.